
Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance
Find the latest Praxis Precision Medicines, Inc. (PRAX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Prax-Client/Releases - GitHub
-- NOTICE: Our server was termed. join the new one at https://prax.wtf/discord! [+] Added InvMove [+] Added new notifications style [+] Added Nuker [+] Added custom killsound to …
PRAX Stock Price | Praxis Precision Medicines Inc. Stock Quote …
2025年3月26日 · PRAX | Complete Praxis Precision Medicines Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
2期临床未达主要终点,市值缩水大半,神经药物领头羊如何翻身?
2023年7月27日 · 治疗局灶性癫痫的prax-628管线预计于第四季度开启2期临床;治疗两类单基因癫痫病的prax-562已获得fda和ema的odd(孤儿药资格)、fda的rpd(罕见儿科疾病资格)认 …
Praxis Precision Medicines - PRAX - Stock Price Today - Zacks
5 天之前 · View Praxis Precision Medicines, Inc PRAX investment & stock information. Get the latest Praxis Precision Medicines, Inc PRAX detailed stock quotes, stock data, Real-Time …
Praxis Precision Medicines (PRAX) Stock Forecast & Price Target
4 天之前 · PRAX's current price target is $123.33. Learn why top analysts are making this stock forecast for Praxis Precision Medicines at MarketBeat.
PRAX-Praxis Precision Medicines, Inc.-基本資料-美股-MoneyDJ …
Praxis Precision Medicines, Inc.(PRAX.US)成立於2015,總部位於美國麻州劍橋,為一家臨床階段的生物製藥公司,將遺傳學見解轉化開發因中樞神經系統(CNS ...
Critical Comparison: Praxis Precision Medicines (NASDAQ:PRAX) …
10 小时之前 · Comparatively, Sycamore Entertainment Group has a beta of 54.56, suggesting that its stock price is 5,356% more volatile than the S&P 500. Analyst Recommendations
PRAX | Praxis Precision Medicines Inc. Advanced Charts - MarketWatch
Praxis Precision Medicines Inc. advanced stock charts by MarketWatch. View PRAX historial stock data and compare to other stocks and exchanges.
From Underdog to Market Darling: How Praxis Precision Is …
2024年11月26日 · Praxis Precision Medicines Inc., identified by the ticker PRAX, has been in the spotlight not just for its relentless focus on neurological drug development but now for its …